MetaVia's DA-1726 completed dose escalation in Phase 1 trials, reaching maximum planned doses in all participants while maintaining tolerability. The drug targets obesity through dual mechanisms—appetite suppression and increased energy expenditure—positioning it as a metabolically distinct candidate from first-generation GLP-1 therapies, with Phase 1 data showing 9.1% weight loss and improved visceral fat distribution at 48 mg dosing.
Key Points
- DA-1726 increases energy expenditure alongside appetite reduction, not appetite suppression alone
- All Phase 1 participants achieved target doses with favorable tolerability profile maintained
- 9.1% weight loss with meaningful visceral fat reduction at 48 mg after eight weeks
Longevity Analysis
The shift from appetite-suppression-only therapies to dual-mechanism drugs that restore energy efficiency addresses a critical gap in metabolic health. Current obesity treatments reduce caloric intake but do not necessarily restore the body's capacity to regulate energy production or metabolic function—a distinction that becomes increasingly relevant for long-term health outcomes beyond weight loss. Visceral fat reduction particularly signals improvement in how the body distributes and stores energy, with implications for cardiovascular and metabolic resilience that extend beyond the scale.
Original published by Longevity.Technology, by Kyle Umipig.